LEADER 01797nam  2200373   450 
001 9910678587303321
005 20230429164929.0
010   $a1-80355-358-8
035   $a(CKB)5840000000237854
035   $a(NjHacI)995840000000237854
035   $a(EXLCZ)995840000000237854
100   $a20230429d2023      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aCOVID-19 Vaccines $eCurrent State and Perspectives /$fby Ibrokhim Y. Abdurakhmonov, editor
210  1$a[Place of publication not identified] :$cIntechOpen,$d2023.
215   $a1 online resource (160 pages)
311   $a1-80355-357-X 
330   $aCOVID-19 Vaccines - Current State and Perspectives provides the reader with the latest overview and opinions on the current state of the art in COVID-19 vaccines, as well as future prospects. The challenges covered include novel vaccine development for the emerging variants of concern (VOCs), vaccine side-effects with real-world examples, population hesitancy, and country experiences with COVID-19 vaccine development, clinical trialing and mass vaccination. Chapters discuss new opinions and directions on the repurposing of existing traditional vaccines with a wide spectrum of action and new platforms for fast-tracked vaccine production and approvals ...
606   $aCOVID-19 (Disease)$xVaccination
606   $aCOVID-19 (Disease)$xPrevention
615  0$aCOVID-19 (Disease)$xVaccination.
615  0$aCOVID-19 (Disease)$xPrevention.
676   $a362.1962414
702   $aAbdurakhmonov$b Ibrokhim Y.
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910678587303321
996   $aCOVID-19 Vaccines$93140609
997   $aUNINA